Cell and Gene Outsourcing

  1. Plasmid Engineering Services For Enhanced Expression And Improved Yields 7/20/2026

    Targeted plasmid design enhances viral vector expression, process yield, and safety. Strategic construct engineering overcomes toxicity and titer bottlenecks to de-risk advanced therapy development.

  2. Selecting A Prefillable Syringe System With Confidence 7/17/2026

    Prefilled syringe selection can stall drug development for months. This system integrates barrel, plunger, and needle shield from a single supplier, reducing complexity for emerging biotech.

  3. Secure Your Custom Media Supply With Capacity And Quality You Can Trust 7/17/2026

    A resilient media supply strategy helps reduce operational risk. Gain insight into how scalable manufacturing, quality alignment, and supplier qualification can strengthen continuity.

  4. When To Conduct GMP Versus Non-GMP Stability Studies — And Why Both Matter 7/15/2026

    Understanding when to leverage GMP vs non-GMP stability studies and where each approach delivers maximum value can help sponsors make better development decisions and reach clinic faster.

  5. NYBCe CCS Apheresis Collection Sites And Capacity 7/13/2026

    Consistent cell sourcing needs precise donor matching, scalable collection, and reliable logistics to cut variability, improve reproducibility, and speed research-to-clinical manufacturing.

  6. Cell Sourcing 7/13/2026

    High-quality cell sourcing combines diverse donors, precise matching, and efficient logistics for consistent material. Global delivery supports scalable, compliant workflows.

  7. Comprehensive Testing Services 7/13/2026

    Better outcomes start with early alignment. Direct, cross-team communication reduces delays, limits surprises, and supports proactive decision-making.

  8. Building CGT Manufacturing Capacity For The Next Commercial Era 7/13/2026

    Recent investments — mostly by CDMOs — are expanding manufacturing capacity to support the growing cell and gene therapy pipeline. We also discuss associated trends and impacts.

  9. CGT Biotech/CDMO Transparency & Core Capabilities 7/9/2026

    This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech sharing what CGT developers should look for in a CDMO partnership, including transparency, data visibility, and capability rather than just capacity. The panelists reinforce that CGT companies should retain deep product knowledge, CMC strategy, quality oversight, and regulatory understanding in-house. 

  10. CGT Modality, Hybrid Models, And What To Keep In-House 7/9/2026

    This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech examining how modality changes the CGT manufacturing decision framework, with autologous programs requiring patient-specific coordination and allogeneic and in vivo approaches opening different paths for scale and inventory.